BioWorld Asia

Sep. 29, 2004

Qiagen Pays $28.5M Cash For Molecular Staging Technology

Qiagen NV is paying $28.5 million in cash to acquire whole-genome amplification technology from Molecular Staging Inc. (BioWorld International) Read More

ExonHit Therapeutics' ALS Drug Fails In Phase III Trial

Cells' Strategy For Rejuvenation Boosts Stem Cell Therapy Hope

France Gives Green Light To Embryonic Stem Cell Imports

Public, Private Sectors At Odds Over German Biotech Direction

Physiomics Enters Deal With Bayer, Eyes IPO On AIM Index

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.